Novo Nordisk sues Eli Lilly, alleging the company's GLP-1 ads are 'deliberately false'
Novo Nordisk sued Eli Lilly, alleging deceptive advertising claims about its weight-loss drug Zepbound compared to Novo Nordisk's Wegovy. The lawsuit claims Eli Lilly's ads use outdated clinical trials comparing different doses and mislead consumers into believing Zepbound is superior. Eli Lilly has defended its advertising and intends to contest the lawsuit.
Mentioned
Related Signal
Adjacent reporting
- Novo Nordisk sues competitor Eli Lilly over GLP-1 advertising
- Novo Nordisk sues Eli Lilly, alleging misleading GLP-1 advertising
- Novo Nordisk sues Eli Lilly over ads comparing GLP-1 medications
- STAT+: Novo Nordisk sues Eli Lilly over GLP-1 drug ads it calls ‘deceptive’
- Novo Nordisk is suing Eli Lilly over ads it says mislead consumers on weight loss drug efficacy
- Novo Nordisk sues Eli Lilly, accusing it of false advertising